However, a larger droplet or particle size reaches only airway mucosa from the larynx to the bronchioles (and often is swallowed from the pharynx) so that virtually none reaches the alveolus
Semaglutide: FDA-approved for weight management (2021) and type 2 diabetes Widely available via prescription Available from research peptide suppliers Established insurance coverage pathways Years of post-marketing safety data Cagrilintide: Not FDA-approved (investigational as of March 2026) Phase 3 REDEFINE trials complete with positive results Available from some research peptide suppliers as a research chemical No insurance coverage Limited long-term safety data (68 weeks maximum from trials) Cost Considerations Without FDA approval, cagrilintide has no established retail price
As a reference standard, high-performance liquid chromatography-tandem mass spectrometry was performed
Taking these medications long-term is associated with an increased risk of serious side effects such as heart attack, stroke, heart failure, gastrointestinal bleeding, ulceration, and perforation, kidney injury, potential liver strain, and serotonin syndrome